Lunesta, Rozerem, and More: Showtime for the New Hypnotics
The Carlat Psychiatry Report, Volume 3, Number 9, September 2005
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Suddenly, putting patients to sleep is all the rage in psychiatry. Over the last year, two new hypnotics have been approved by the FDA – Lunesta (eszopiclone) in December 2004 and Rozerem (ramelteon) in July 2005. Indiplon (the generic name) is on the launching pad for approval in early 2006.